Detection of Minimal Residual Disease in Acute Myeloid Leukemia: Evaluating Utility and Challenges
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
Follow-up data from the 20 patients in the article.
应用场景：
创建时间：
2024-06-05
相关数据集
Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia [barcode-seq SG12]
Targeting the MYST acetyltransferases are an exciting therapeutic opportunity in acute myeloid leukaemia (AML). Here we define the individual and combined contribution of KAT6A, KAT6B and KAT7, in ran
NIAID Data Ecosystem90
Supplementary Table 2 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia
Transcription Factor Enrichment Analysis of MOLM13 Bulk RNA-Seq (24 Hours After Drug Treatment)
Figshare2023-07-05 更新40
Role of Branched Chain Amino Acid Transaminase 1 (BCAT1) in Acute Myeloid Leukemia [expression_BCAT1-KD #2]
The branched chain amino acid (BCAA) pathway and high levels of BCAA transaminase 1 (BCAT1) have recently been associated with aggressiveness in several cancer entities. However, the mechanistic role
NIAID Data Ecosystem30
RNA sequencing expression analysis of murine MLL-AF9;NRAS acute myeloid leukemia cells silenced for E2-2.
We investigated the role of the transcriptional regulators Id2 and E2-2 (encoded by Tcf4) in the context of MLL-rearranged acute myeloid leukemia (AML). Using an AML mouse model driven by a Tet-off in
干细胞与再生医学数据中心2022-02-20 更新80
DataSheet_1_Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML.zip
BackgroundNPM1 mutation status can influence prognosis and management in AML. Accordingly, clinical testing (i.e., RT-PCR, NGS and IHC) for mutant NPM1 is increasing in order to detect residual diseas
NIAID Data Ecosystem30
